GO:0090108 positive regulation of high-density lipoprotein particle assembly: Metabolic Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0090108 describes any process that increases the frequency, rate, or extent of high-density lipoprotein (HDL) particle assembly, a key step in reverse cholesterol transport.
• HDL assembly requires the aggregation of apolipoproteins (primarily APOA1) with lipids, and its positive regulation influences plasma HDL levels and cardiovascular risk.
• PCSK9 modulates HDL metabolism, and its inhibition or deficiency can raise HDL levels, linking GO:0090108 to therapeutic strategies.
• Dietary carbohydrate restriction positively affects atherogenic dyslipidemia, partly by enhancing HDL assembly and function.
• Genetic and genomic studies in model organisms, such as the Weddell seal, reveal selection on lipid handling pathways that include HDL regulation.
• Low hepatic stearoyl-CoA desaturase 1 (SCD1) activity is associated with fatty liver and insulin resistance, conditions that can impair HDL assembly.
Description
High-density lipoprotein (HDL) particles are central to reverse cholesterol transport, removing excess cholesterol from peripheral tissues to the liver for excretion. The assembly of HDL particles is a tightly regulated process that involves the lipidation of apolipoprotein A-I (APOA1) and the incorporation of phospholipids and cholesterol. GO:0090108, positive regulation of high-density lipoprotein particle assembly, encompasses any molecular event that increases the frequency, rate, or extent of this assembly process. Understanding this regulation is critical because HDL levels and functionality are inversely associated with cardiovascular disease risk, and modulating HDL assembly could offer therapeutic benefits. Research into GO:0090108 has revealed that multiple factors, including dietary composition, hormonal signals, and genetic variants, influence HDL assembly. For instance, carbohydrate-restricted diets can improve atherogenic dyslipidemia by enhancing HDL assembly and maturation. Additionally, comparative genomics has identified selection signatures in lipid-handling genes in species adapted to extreme environments, providing insights into conserved regulatory mechanisms. Dysregulation of HDL assembly is linked to metabolic disorders such as fatty liver disease and insulin resistance, where hepatic lipid metabolism is altered. Therefore, studying the positive regulation of HDL particle assembly at the molecular level is essential for developing targeted interventions. This article synthesizes current knowledge on GO:0090108, covering its definition, key genes, regulatory mechanisms, disease associations, and experimental approaches, including CRISPR-based models.
positive regulation of high-density lipoprotein particle assembly At A Glance
| GO ID | GO:0090108 |
|---|---|
| GO term | positive regulation of high-density lipoprotein particle assembly |
| Ontology | biological_process |
| Synonym | none |
| Major function | Increases the rate or extent of HDL particle assembly, contributing to reverse cholesterol transport and lipid homeostasis. |
| Related process | High-density lipoprotein particle assembly (GO:0034380) |
| Regulatory direction | Positive (upregulation) |
| Taxonomic range | Eukaryotes, primarily vertebrates |
| Common experimental models | Mouse, rat, human cell lines (e.g., HepG2, primary hepatocytes) |
What Is GO:0090108?
GO:0090108, positive regulation of high-density lipoprotein particle assembly, is a biological process that increases the frequency, rate, or extent of HDL particle assembly. HDL particle assembly itself is the aggregation and arrangement of proteins and lipids to form a high-density lipoprotein particle. This term specifically covers the positive regulatory events, such as signaling pathways or molecular interactions, that enhance the assembly process, rather than the assembly steps themselves.
Why Is positive regulation of high-density lipoprotein particle assembly Important in Cell Biology?
Positive regulation of HDL particle assembly is crucial for maintaining plasma HDL levels and functionality, which are inversely correlated with atherosclerosis and cardiovascular disease. Enhancing HDL assembly can promote reverse cholesterol transport, reducing cholesterol accumulation in arteries. Moreover, understanding this process illuminates how diet, genes, and drugs modulate HDL, offering avenues for therapeutic intervention in dyslipidemia and metabolic syndrome.
• Maintains plasma HDL levels, a negative risk factor for cardiovascular disease.
• Promotes reverse cholesterol transport, removing excess cholesterol from peripheral tissues.
• Influenced by dietary factors such as carbohydrate restriction, which can improve atherogenic dyslipidemia.
• Modulated by PCSK9, a drug target for lowering LDL and potentially raising HDL.
• Genetic selection in extreme environments highlights conserved lipid-handling pathways.
• Impaired regulation is associated with fatty liver disease and insulin resistance.
• Key for understanding inter-individual variability in HDL levels and function.
• Potential target for therapies aimed at raising functional HDL.
• Provides insights into metabolic syndrome and obesity-related dyslipidemia.
• Serves as a model for studying complex trait regulation at the molecular level.
What Happens During positive regulation of high-density lipoprotein particle assembly?
Initiation of HDL Assembly
In simple terms: The process starts when apolipoprotein A-I (APOA1) is produced and begins to acquire lipids.
HDL assembly begins with the synthesis of APOA1 in the liver and intestine. APOA1 is secreted as a lipid-poor apolipoprotein and interacts with cellular lipid transporters such as ABCA1, which facilitates the transfer of phospholipids and cholesterol to APOA1, forming nascent HDL. Positive regulation at this stage can involve increased APOA1 expression or enhanced ABCA1 activity, leading to more efficient lipidation.
Lipidation and Maturation
In simple terms: Nascent HDL particles grow by taking up more lipids and interacting with enzymes.
Nascent HDL particles undergo further lipidation via the action of lecithin-cholesterol acyltransferase (LCAT), which esterifies free cholesterol, driving the maturation of HDL into spherical particles. Positive regulation can occur through increased LCAT activity or enhanced lipid availability. Additionally, phospholipid transfer protein (PLTP) and cholesteryl ester transfer protein (CETP) modulate HDL size and composition, and their regulation can impact assembly.
Role of PCSK9 in HDL Regulation
In simple terms: PCSK9, a protein that regulates cholesterol, also affects HDL assembly.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is primarily known for degrading the LDL receptor, but it also influences HDL metabolism. Experimental animal models and clinical evidence indicate that PCSK9 inhibition or deficiency can lead to increased HDL levels, suggesting a role in positively regulating HDL assembly. The exact mechanisms may involve modulation of hepatic lipase or other pathways affecting HDL remodeling.
Dietary and Metabolic Influences
In simple terms: What you eat and your metabolic state can boost HDL assembly.
Dietary carbohydrate restriction induces a unique metabolic state that positively affects atherogenic dyslipidemia, including raising HDL levels. This may occur through increased fatty acid oxidation and altered hepatic lipid handling, which can enhance APOA1 lipidation and HDL assembly. Similarly, low hepatic stearoyl-CoA desaturase 1 (SCD1) activity is associated with fatty liver and insulin resistance, conditions that may impair HDL assembly, implying that normal SCD1 activity supports optimal HDL formation.
Genetic and Evolutionary Perspectives
In simple terms: Some animals have evolved special lipid handling that can teach us about HDL regulation.
The Antarctic Weddell seal genome reveals evidence of selection on cardiovascular phenotype and lipid handling, including genes related to HDL metabolism. This suggests that positive regulation of HDL assembly may be under evolutionary pressure in species adapted to extreme environments, offering insights into conserved regulatory mechanisms that could be targeted in humans.
Key Genes Involved in GO:0090108 positive regulation of high-density lipoprotein particle assembly
The following genes and proteins are key players in the positive regulation of HDL particle assembly, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| APOA1 | Main apolipoprotein component of HDL; acceptor for lipid efflux | Central to HDL assembly; mutations cause low HDL and amyloidosis |
| ABCA1 | Cholesterol efflux transporter; lipidates APOA1 | Defects cause Tangier disease; target for enhancing HDL assembly |
| LCAT | Esterifies cholesterol on HDL; drives maturation | Deficiency leads to fish-eye disease and low HDL |
| PCSK9 | Regulates LDL receptor and modulates HDL metabolism | Inhibition raises HDL in some studies; drug target |
| SCD1 | Desaturase involved in fatty acid synthesis; affects lipid metabolism | Low activity linked to fatty liver and insulin resistance |
| CETP | Transfers cholesteryl esters between lipoproteins | Inhibition raises HDL; target for cardiovascular therapy |
| PLTP | Transfers phospholipids; remodels HDL | Impacts HDL size and function |
| LIPC | Hepatic lipase; hydrolyzes HDL lipids | Modulates HDL levels; variants affect HDL cholesterol |
| LPL | Lipoprotein lipase; hydrolyzes triglycerides | Provides lipids for HDL assembly |
| ABCG1 | Cholesterol efflux transporter to HDL | Contributes to HDL maturation |
| SR-BI | HDL receptor; mediates selective cholesterol uptake | Regulates HDL clearance and reverse transport |
| APOA2 | Second major HDL apolipoprotein | Modulates HDL structure and function |
| APOC3 | Inhibits lipoprotein lipase; affects HDL | Variants linked to dyslipidemia |
| ANGPTL3 | Inhibits lipoprotein lipase | Inhibition lowers triglycerides and may raise HDL |
| NR1H3 (LXRα) | Nuclear receptor; regulates cholesterol efflux genes | Activation promotes HDL assembly |
| PPARG | Nuclear receptor; regulates lipid metabolism | Agonists affect HDL levels |
| SREBF1 | Transcription factor; regulates lipogenic genes | Influences lipid availability for HDL assembly |
How Is positive regulation of high-density lipoprotein particle assembly Regulated?
The positive regulation of HDL particle assembly is controlled at multiple levels. Transcriptional regulation of APOA1, ABCA1, and other genes by nuclear receptors such as LXR and PPARα can enhance assembly capacity. Post-translational modifications of APOA1 and enzymes like LCAT also modulate activity. Hormonal signals, including insulin and estrogen, influence HDL metabolism. Additionally, PCSK9 affects HDL levels, and its inhibition may positively regulate assembly. Dietary factors, such as carbohydrate restriction, can induce metabolic states that favor HDL assembly. Genetic variation in genes like SCD1 can impact hepatic lipid handling and thus HDL formation.
positive regulation of high-density lipoprotein particle assembly and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| APOA1 | Low HDL, cardiovascular disease, amyloidosis | Apoa1 knockout mouse; overexpression in hepatocytes |
| ABCA1 | Tangier disease, low HDL | Abca1 knockout mouse; human cell lines with ABCA1 mutations |
| LCAT | Fish-eye disease, corneal opacities, low HDL | Lcat knockout mouse; recombinant LCAT administration |
| PCSK9 | Hypercholesterolemia, cardiovascular disease | Pcsk9 knockout mouse; human clinical trials with inhibitors |
| SCD1 | Fatty liver, insulin resistance | Scd1 knockout mouse; human hepatocyte models |
Cardiovascular Disease and Atherosclerosis
Low HDL cholesterol is a well-established risk factor for atherosclerosis and coronary heart disease. Positive regulation of HDL assembly enhances reverse cholesterol transport, potentially reducing plaque formation. Therapies that boost HDL assembly, such as APOA1 mimetics or LXR agonists, are under investigation. PCSK9 inhibitors, while primarily lowering LDL, may also modestly raise HDL, contributing to cardiovascular benefit.
Metabolic Syndrome and Type 2 Diabetes
Metabolic syndrome is characterized by low HDL, high triglycerides, and insulin resistance. Dietary carbohydrate restriction improves atherogenic dyslipidemia partly by increasing HDL levels, likely through enhanced HDL assembly. Insulin resistance is associated with impaired HDL assembly, and low hepatic SCD1 activity is linked to fatty liver and insulin resistance, conditions that can further compromise HDL formation.
Fatty Liver Disease
Nonalcoholic fatty liver disease (NAFLD) is often accompanied by low HDL and dysfunctional HDL particles. Low hepatic SCD1 activity is associated with fatty liver and insulin resistance in obese humans, suggesting that altered lipid desaturation may impair HDL assembly. Enhancing HDL assembly could be a therapeutic strategy for NAFLD, though more research is needed.
From positive regulation of high-density lipoprotein particle assembly-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X positively regulate HDL assembly? | Knockout of gene X in HepG2 or primary hepatocytes, measure HDL assembly |
| Does a specific point mutation in APOA1 affect HDL assembly? | Knock-in of mutant APOA1 in mouse liver or human cell lines |
| Can overexpression of ABCA1 enhance HDL assembly? | Overexpression of ABCA1 in hepatocytes or transgenic mice |
| What is the role of PCSK9 in HDL assembly? | PCSK9 knockout or overexpression models, measure HDL |
| How does SCD1 activity influence HDL assembly? | SCD1 knockout or pharmacological inhibition in hepatocytes |
| Does a tagged APOA1 allow tracking of HDL assembly? | Knock-in of tagged APOA1 in cell lines, imaging and proteomics |
How to Study the positive regulation of high-density lipoprotein particle assembly Process
| Method | What It Measures | Typical Application |
|---|---|---|
| HDL-C enzymatic assay | HDL cholesterol concentration | Clinical and preclinical samples |
| FPLC | Lipoprotein particle size distribution | Plasma or cell culture media |
| Cholesterol efflux assay | Ability of cells to transfer cholesterol to APOA1 | Macrophages, hepatocytes |
| RNA-seq | Transcriptome changes | Gene expression profiling after perturbations |
| CRISPR knockout screen | Genes required for HDL assembly | Functional genomics in cell lines |
| CRISPR knock-in | Effect of specific mutations | APOA1 or ABCA1 variants |
| Overexpression | Gain-of-function effects | Candidate positive regulators |
| Proteomics | Protein composition of HDL particles | Isolated HDL from plasma or media |
Lipid and Lipoprotein Profiling
Measuring HDL cholesterol and apolipoprotein levels is fundamental. Techniques include enzymatic assays for HDL-C, FPLC for lipoprotein separation, and mass spectrometry for apolipoprotein quantification. These methods assess the outcome of positive regulation on HDL assembly.
Cellular HDL Assembly Assays
In vitro models using hepatocytes or macrophages can measure cholesterol efflux to APOA1 and subsequent HDL particle formation. Radioactive or fluorescent cholesterol tracers, combined with gel filtration or native PAGE, allow quantification of nascent HDL.
Gene Expression and Regulation Studies
RNA-seq and qPCR can quantify expression of genes involved in HDL assembly, such as APOA1, ABCA1, and LCAT. ChIP-seq can identify transcription factor binding sites. These methods reveal how positive regulators influence gene expression.
CRISPR-Based Functional Genomics
CRISPR knockout, knock-in, and overexpression screens can identify novel regulators of HDL assembly. Pooled screens with readouts like HDL-C levels or cholesterol efflux can uncover genes that positively regulate the process.
How CRISPR Can Be Used to Study GO:0090108 positive regulation of high-density lipoprotein particle assembly
Knockout
CRISPR knockout of candidate genes (e.g., APOA1, ABCA1, PCSK9) in hepatocyte cell lines or mouse models can determine whether they are necessary for HDL assembly. Loss of positive regulators should reduce HDL formation, which can be measured by HDL-C assays or cholesterol efflux.
Point Mutation
Introducing specific point mutations (e.g., in APOA1 or LCAT) via CRISPR base editing or homology-directed repair can model human genetic variants and assess their impact on HDL assembly. This helps establish causality for missense variants identified in patients.
Knock-in
Knock-in of tagged or humanized genes (e.g., tagged APOA1) allows tracking of HDL assembly in real time using imaging or proteomics. Knock-in of disease-associated variants can create accurate disease models for drug testing.
Overexpression
CRISPR activation (CRISPRa) or transgenic overexpression of candidate positive regulators (e.g., ABCA1, LXR) can test whether increased expression enhances HDL assembly. This approach is useful for validating gain-of-function hypotheses.
How EDITGENE Supports positive regulation of high-density lipoprotein particle assembly Research
Researchers studying positive regulation of high-density lipoprotein particle assembly-related genes often need to determine whether a candidate gene is causally involved in HDL formation or merely correlated. EDITGENE provides a comprehensive suite of CRISPR services to enable such functional validation, from knockout to precise point mutations and overexpression, accelerating discoveries in lipid metabolism.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of high-density lipoprotein particle assembly research.
Frequently Asked Questions About positive regulation of high-density lipoprotein particle assembly
What is GO:0090108?
GO:0090108 is a Gene Ontology term for positive regulation of high-density lipoprotein particle assembly, describing processes that increase the rate or extent of HDL formation.
What genes are involved in positive regulation of HDL particle assembly?
Key genes include APOA1, ABCA1, LCAT, PCSK9, SCD1, CETP, PLTP, and nuclear receptors like LXR and PPARα.
How does PCSK9 affect HDL assembly?
PCSK9 modulates HDL metabolism; its inhibition or deficiency can raise HDL levels, suggesting a role in positive regulation.
Can diet influence HDL particle assembly?
Yes, dietary carbohydrate restriction positively affects atherogenic dyslipidemia and can enhance HDL assembly.
What diseases are linked to impaired HDL assembly?
Cardiovascular disease, metabolic syndrome, type 2 diabetes, and fatty liver disease are associated with dysregulated HDL assembly.
What experimental models are used to study HDL assembly?
Common models include hepatocyte cell lines (HepG2), primary hepatocytes, and mouse models with gene knockouts or transgenes.
How can CRISPR help study positive regulation of HDL assembly?
CRISPR knockout, knock-in, point mutation, and overexpression can validate gene function and identify novel regulators.
What is the role of SCD1 in HDL assembly?
Low hepatic SCD1 activity is associated with fatty liver and insulin resistance, conditions that may impair HDL assembly.
Are there evolutionary insights into HDL regulation?
Yes, the Weddell seal genome shows selection on lipid-handling genes, including those related to HDL.
What methods measure HDL assembly?
Methods include HDL-C assays, FPLC, cholesterol efflux assays, and proteomics.
Conclusion
Positive regulation of high-density lipoprotein particle assembly (GO:0090108) is a critical biological process that influences plasma HDL levels and cardiovascular health. Key genes such as APOA1, ABCA1, and PCSK9 modulate this process, and its dysregulation is linked to metabolic and cardiovascular diseases. Advances in CRISPR-based models and functional genomics are poised to uncover new regulatory mechanisms and therapeutic targets. EDITGENE's services support these efforts by providing precise gene editing tools for HDL research.
References
- 1. Pillarisetti S. 2000. Lipoprotein modulation of subendothelial heparan sulfate proteoglycans (perlecan) and atherogenicity.. Trends Cardiovasc Med 10(2):60-5 PMID: 11150731
- 2. Ferri N et al.. 2016. Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence.. Transl Res 173:19-29 PMID: 26548330
- 3. Volek JS et al.. 2008. Dietary carbohydrate restriction induces a unique metabolic state positively affecting atherogenic dyslipidemia, fatty acid partitioning, and metabolic syndrome.. Prog Lipid Res 47(5):307-18 PMID: 18396172
- 4. Noh HJ et al.. 2022. The Antarctic Weddell seal genome reveals evidence of selection on cardiovascular phenotype and lipid handling.. Commun Biol 5(1):140 PMID: 35177770
- 5. Stefan N et al.. 2008. Low hepatic stearoyl-CoA desaturase 1 activity is associated with fatty liver and insulin resistance in obese humans.. Diabetologia 51(4):648-56 PMID: 18286258
